Renal Cell Carcinoma
Conditions
Keywords
Renal Cell Carcinoma, TKI, Turkey, Observational
Brief summary
This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician. Duration and dosage of treatment is solely at the discretion of the attending physician. The primary objective of this study is to assess duration of treatment in Turkish renal cell carcinoma patients treated with TKIs (Tyrosine Kinase Inhibitors) who could not tolerate prior cytokine treatment within the first month of treatment.
Interventions
OTHERNo intervention
All dosage, frequency and duration for drugs will be under the decision of the treating physician
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* To be diagnosed as metastatic renal cell carcinoma * Previous cytokine therapy * To sign informed consent form (ICF)
Exclusion criteria
* Patients not willing to sign informed consent form or who withdraw their consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product | After 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of treatment-emergent adverse events (TEAE) | After 2 years |
| Change of Tumor status | Baseline and 2 years |
Countries
Turkey (Türkiye)
Outcome results
None listed